Articole cu mandate pentru acces public - Panos ZanosAflați mai multe
Nu sunt disponibile nicăieri: 2
790. Ketamine Exerts NMDAR Inhibition-Independent Antidepressant Actions via Its Hydroxynorketamine Metabolites
P Zanos, R Moaddel, P Morris, P Georgiou, J Fischell, G Elmer, ...
Biological Psychiatry 81 (10), S321, 2017
Mandate: US National Institutes of Health
80. Theories on the Mechanism of Action of Ketamine: From NMDA Receptor Inhibition to the (2R, 6R)-HNK Metabolite
C Zarate, T Gould, P Zanos, R Machado-Vieira
Biological Psychiatry 81 (10), S33-S34, 2017
Mandate: US National Institutes of Health
Disponibile undeva: 50
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
P Zanos, R Moaddel, PJ Morris, P Georgiou, J Fischell, GI Elmer, ...
Nature 533 (7604), 481-486, 2016
Mandate: US National Institutes of Health
Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms
P Zanos, R Moaddel, PJ Morris, LM Riggs, JN Highland, P Georgiou, ...
Pharmacological reviews 70 (3), 621-660, 2018
Mandate: US National Institutes of Health
Mechanisms of ketamine action as an antidepressant
P Zanos, TD Gould
Molecular psychiatry 23 (4), 801-811, 2018
Mandate: US National Institutes of Health
Convergent mechanisms underlying rapid antidepressant action
P Zanos, SM Thompson, RS Duman, CA Zarate, TD Gould
CNS drugs 32, 197-227, 2018
Mandate: US National Institutes of Health
Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function
EW Lumsden, TA Troppoli, SJ Myers, P Zanos, Y Aracava, J Kehr, J Lovett, ...
Proceedings of the National Academy of Sciences 116 (11), 5160-5169, 2019
Mandate: US National Institutes of Health, US Department of Veterans Affairs
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions
P Zanos, JN Highland, BW Stewart, P Georgiou, CE Jenne, J Lovett, ...
Proceedings of the National Academy of Sciences 116 (13), 6441-6450, 2019
Mandate: US National Institutes of Health, US Department of Veterans Affairs
Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters
A Can, P Zanos, R Moaddel, HJ Kang, KSS Dossou, IW Wainer, JF Cheer, ...
The Journal of Pharmacology and Experimental Therapeutics 359 (1), 159-170, 2016
Mandate: US National Institutes of Health
The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition
P Zanos, SC Piantadosi, HQ Wu, HJ Pribut, MJ Dell, A Can, ...
The Journal of pharmacology and experimental therapeutics 355 (1), 76-85, 2015
Mandate: US National Institutes of Health
Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor
P Georgiou, P Zanos, TCM Mou, X An, DM Gerhard, DI Dryanovski, ...
Nature neuroscience 25 (9), 1191-1200, 2022
Mandate: US National Institutes of Health, US Department of Veterans Affairs
A negative allosteric modulator for alpha5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA …
P Zanos, ME Nelson, JN Highland, SR Krimmel, P Georgiou, TD Gould, ...
eneuro, 2017
Mandate: US National Institutes of Health
Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
PJ Morris, R Moaddel, P Zanos, CE Moore, T Gould, CA Zarate Jr, ...
Organic letters 19 (17), 4572-4575, 2017
Mandate: US National Institutes of Health
Animal models to improve our understanding and treatment of suicidal behavior
TD Gould, P Georgiou, LA Brenner, L Brundin, A Can, P Courtet, ...
Translational psychiatry 7 (4), e1092-e1092, 2017
Mandate: US National Institutes of Health, US Department of Veterans Affairs …
(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses
P Zanos, JN Highland, X Liu, TA Troppoli, P Georgiou, J Lovett, PJ Morris, ...
British journal of pharmacology 176 (14), 2573-2592, 2019
Mandate: US National Institutes of Health, US Department of Veterans Affairs
Hydroxynorketamines: pharmacology and potential therapeutic applications
JN Highland, P Zanos, LM Riggs, P Georgiou, SM Clark, PJ Morris, ...
Pharmacological reviews 73 (2), 763-791, 2021
Mandate: US National Institutes of Health, US Department of Veterans Affairs
Dopamine and stress system modulation of sex differences in decision making
P Georgiou, P Zanos, S Bhat, JK Tracy, IJ Merchenthaler, MM McCarthy, ...
Neuropsychopharmacology 43 (2), 313-324, 2018
Mandate: US National Institutes of Health
Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism
P Zanos, SR Wright, P Georgiou, JH Yoo, C Ledent, SM Hourani, I Kitchen, ...
Pharmacology Biochemistry and Behavior 119, 72-79, 2014
Mandate: European Commission
Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine
JN Highland, PJ Morris, P Zanos, J Lovett, S Ghosh, AQ Wang, ...
Journal of Psychopharmacology 33 (1), 12-24, 2019
Mandate: US National Institutes of Health
A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression
LT Park, B Kadriu, TD Gould, P Zanos, D Greenstein, JW Evans, P Yuan, ...
International Journal of Neuropsychopharmacology 23 (7), 417-425, 2020
Mandate: US National Institutes of Health, US Department of Veterans Affairs
Informațiile despre publicații și finanțare sunt alese automat de un program informatic